|Aegis Capital Corp.|
|810 Seventh Avenue, 18 th Floor|
|New York, New York 10019|
Trade-Ideas LLC identified CytRx (CYTR) as a weak on high relative volume candidate
The aldoxorubicin sarcoma study failure leaves CytRx with a depleted pipeline and 40 cents per share in cash.